NCT05933395 2026-01-20
GERTRUDE
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
Clinical Trials
14 trialsNCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT00640978 2025-05-01
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01678664 2024-09-25
EVACEL
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT02915783 2023-01-17
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Eisai Inc.
Phase 2 Completed
NCT00830895 2022-11-09
RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
Seoul National University Hospital
Phase 2 Completed
NCT04355858 2022-07-26
MULAN
Fudan University
Phase 2 Unknown
NCT01499160 2022-02-11
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
University of Maryland, Baltimore
Phase 2 Terminated
NCT01783444 2021-02-26
BOLERO-6
Novartis
Phase 2 Completed
NCT01648465 2019-09-03
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
Hellenic Cooperative Oncology Group
Phase 2 Terminated
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00529802 2018-04-25
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
University of Chicago
Phase 2 Completed
NCT01178151 2015-04-22
EVAMP
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Withdrawn
NCT01127763 2014-04-09
RAD001 Plus Carboplatin in Breast Cancer Patients
NYU Langone Health
Phase 2 Completed